Article

Enrollment complete for trabeculoplasty trial

Patient enrollment in a multicenter trial to study trabeculoplasty performed with a titanium-sapphire laser (SOLX 790, OccuLogix) is complete, according to the laser's manufacturer.

Boston-Patient enrollment in a multicenter trial to study trabeculoplasty performed with a titanium-sapphire laser (SOLX 790, OccuLogix) is complete, according to the laser's manufacturer. The research is being conducted in more than 160 eyes in an effort to obtain 510(k) clearance from the FDA.

Enrollees are patients with primary open-angle glaucoma in eyes with poorly controlled IOP on maximally tolerated medications or prior failed glaucoma surgery. Patients were randomly assigned to undergo outpatient treatment with the titanium-sapphire laser or with an argon laser. Each group contains a similar number of eyes, and each of the investigational sites-in the United States, Canada, Israel, and Spain-has a similar number of eyes enrolled. Preliminary review of the data shows consistent, equivalent IOP reduction in patients in both groups followed for up to 1 year, according to the company.

"This laser is the first of its kind to use the 790-nm wavelength, which has been shown to penetrate the tissue deeper than other laser trabeculoplasty procedures while preserving the integrity of the trabecular meshwork," said Doug Adams, chief executive officer and founder of SOLX, the glaucoma division of OccuLogix.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.